乙型肝炎病毒耐药性研究进展  

Progress in research on hepatitis B virus resistance

作　　者：张劲丰[1] 安宏亮[1] 苏荣[1] 吕微风 ZHANG Jinfeng;AN Hongliang;SU Rong;LV Weifeng(Department of Clinical Laboratory,Foshan hospital of traditional Chinese medicine,Foshan,Guangdong,China,528000)

机构地区：[1]佛山市中医院检验医学中心，广东 佛山 528000

出　　处：《分子诊断与治疗杂志》2019年第5期434-440,共7页Journal of Molecular Diagnostics and Therapy

摘　　要：乙型肝炎病毒(HBV)是导致慢性乙型肝炎(CHB)和原发性肝细胞癌(HCC)的重要原因之一。核苷(酸)类似物和干扰素已被证明可以有效控制HBV,降低肝癌的发生率。然而,HBV耐药性的产生限制了抗病毒类药物长期有效性,其耐药机制的研究对新的抗病毒药物的研发十分关键。本文对HBV抗病毒药物作用机制、耐药性产生机制及耐药性预防策略进行系统综述,以期为HBV新抗病毒药物的开发及临床治疗提供参考意见。Hepatitis B virus(HBV)is one of the important causes of chronic hepatitis B(CHB)and primary hepatocellular carcinoma(HCC).Nucleos(t)ide analogues and interferons have been shown to be effective in controlling HBV and reducing the incidence of liver cancer.However,the development of HBV resistance limits the long?term effectiveness of antiviral drugs,and the study of drug resistance mechanisms is critical for the development of new antiviral drugs.This article reviews the mechanism of action of HBV antivi?ral drugs,the mechanism of drug resistance and the prevention strategy of drug resistance,in order to provide reference for the development and clinical treatment of new antiviral drugs for HBV.

关 键 词：乙型肝炎病毒 耐药性 核苷(酸)类似物 干扰素 药物靶标 

分 类 号：R51[医药卫生—内科学]